FHIT, at a constitutively active chromosome fragile site, is often a target of chromosomal aberrations and deletion in a large fraction of human tumors. Inactivation of murine Fhit allelessignificantly increases susceptibility of mice to spontaneous and carcinogen-induced tumorigenesis. In this study, transgenic mice, carrying a human FHIT cDNA under control of the endogenous promoter, were produced to determine the effect of Fhit expression, from a nonfragile cDNA transgene outside the fragile region, on carcinogen-induced tumor susceptibility of wildtype and Fhit heterozygous mice. Mice received sufficient oral doses of N-nitrosomethybenzylamine (NMBA) to cause forestomach tumors in >80% of nontransgenic control mice. Although the level of expression of the FHIT transgene in the recombinant mouse strains was much lower than the level of endogenous Fhit expression, the tumor burden in NMBA-treated male transgenic mice was significantly reduced, while female transgenic mice were not protected. To determine if the difference in protection could be due to differences in epigenetic changes at the transgene loci in male versus female mice, we examined expression, hypermethylation and induced re-expression of FHIT transgenes in male and female mice or cells derived from them. The transgene was methylated in male and female mice and in cell lines established from male and female transgenic kidneys, the FHIT locus was both hypermethylated and deacetylated. It is likely that the FHIT transgene is more tightly silenced in female transgenic mice, leading to a lack of protection from tumor induction.

1.
Bird AP: DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21 (2002).
2.
Bird AP, Wolffe AP: Methylation-induced repression-belts, braces, and chromatin. Cell 99:451–454 (1999).
3.
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 265:1287–1289 (1991).
4.
Druck T, Hadaczek P, Fu T-B, Ohta M, Siprashvili Z, et al: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 61:4827–4836 (1997).
5.
Dumon KR, Ishii H, Fong LYY, Zanesi N, Fidanza V, et al: FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98:3346–3351 (2001).
6.
Fong LYY, Magee PN: Dietary zinc deficiency enhances esophageal cell proliferation and N- nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6J mouse. Cancer Lett 143:63–69 (1999).
7.
Fong LYY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, et al: Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 97:4742–4747 (2000).
8.
Giraldo P, Montoliu L: Size matters: use of YACs, BACs, and PACs in transgenic animals. Transgenic Res 10:83–103 (2001).
9.
Glover TW, Hoge AW, Miller DE, Ascara-Wilke JE, Adam AN, et al: The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. Cancer Res 58:3409–3414 (1998).
10.
Han SY, Iliopolous D, Druck T, Guler G, Grubbs CJ, et al: CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors. Oncogene 23:3990–3998 (2004).
11.
Huebner K, Croce CM: Cancer and the FRA3B/FHIT fragile locus: it’s a Hit. Brit J Cancer 88:1501–1506 (2003).
12.
Ishii H, Zanesi N, Vecchione A, Trapasso F, Yendamuri S, et al: Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J 17:1768–1770 (2003).
13.
Ishii H, Vecchione A, Fong LY, Zanesi N, Trapasso F, et al: Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses. Curr Gene Ther 4:53–63 (2004).
14.
Matsuyama A, Shiraishi T, Trapasso F, Kuroki T, Alder H, et al: Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci USA 100:14988–14993 (2003).
15.
Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587–597 (1996).
16.
Ottey M, Han SY, Druck T, Barnoski BL, McCorkell KA, et al: Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 91:1669–1677 (2004).
17.
Paradee W, Wilke CM, Wang L, Shridhar R, Mullins CM, et al: A 350-kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints. Genomics 35:87–93 (1996).
18.
Pekarsky Y, Druck T, Cotticelli MG, Ohta M, Shou J, et al: The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells. Cancer Res 58:3401–3408 (1998).
19.
Pena RN, Webster J, Kwan S, Korbel J, Whitelaw BA: Transgene methylation in mice reflects copy number but not expression level. Mol Biotech 26:215–219 (2004).
20.
Pinkel D, Straume T, Gray JW: Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 83:2934–2938 (1986).
21.
Seabright M: A rapid banding technique for human chromosomes. Lancet 2:971–972 (1971).
22.
Shi YP, Huang TT, Carlson EJ, Epstein CJ: The mapping of transgenes by fluorescence in situ hybridization on G-banded mouse chromosomes. Mamm Genome 5:337–341 (1994).
23.
Yunis JJ, Sorenga AL: Constitutive fragile sites and cancer. Science 226:1199–1204 (1994).
24.
Zanesi N, Fidanza V, Fong LYY, Mancini R, Druck T, et al: The tumor spectrum in Fhit-deficient mice. Proc Natl Acad Sci USA 98:10250–10255 (2001).
25.
Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Goradts J, et al: 5′CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61:3581–3585 (2001).
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.